title: Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
authors.affiliation: Fox Chase Comprehensive Cancer Center, Philadelphia, PA 1911-2412, USA. RJ_Schilder@fccc.edu
authors.forename: Russell
authors.initials: R
authors.lastname: Schilder
authors.forename: Arturo
authors.initials: A
authors.lastname: Molina
authors.forename: Nancy
authors.initials: N
authors.lastname: Bartlett
authors.forename: Thomas
authors.initials: T
authors.lastname: Witzig
authors.forename: Leo
authors.initials: L
authors.lastname: Gordon
authors.forename: James
authors.initials: J
authors.lastname: Murray
authors.forename: Stewart
authors.initials: S
authors.lastname: Spies
authors.forename: Hua
authors.initials: H
authors.lastname: Wang
authors.forename: Gregory
authors.initials: G
authors.lastname: Wiseman
authors.forename: Christine
authors.initials: C
authors.lastname: White
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000401:mortality / Q000532:radiotherapy*; D008224:Lymphoma, Follicular / Q000401:mortality / Q000532:radiotherapy*; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy; D013921:Thrombocytopenia / Q000401:mortality / Q000532:radiotherapy*; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan